[HTML][HTML] Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein …
N Fisher, R Abd Majid, T Antoine, M Al-Helal… - Journal of Biological …, 2012 - ASBMB
Atovaquone is an anti-malarial drug used in combination with proguanil (eg Malarone TM)
for the curative and prophylactic treatment of malaria. Atovaquone, a 2-
hydroxynaphthoquinone, is a competitive inhibitor of the quinol oxidation (Q o) site of the
mitochondrial cytochrome bc 1 complex. Inhibition of this enzyme results in the collapse of
the mitochondrial membrane potential, disruption of pyrimidine biosynthesis, and
subsequent parasite death. Resistance to atovaquone in the field is associated with point …
for the curative and prophylactic treatment of malaria. Atovaquone, a 2-
hydroxynaphthoquinone, is a competitive inhibitor of the quinol oxidation (Q o) site of the
mitochondrial cytochrome bc 1 complex. Inhibition of this enzyme results in the collapse of
the mitochondrial membrane potential, disruption of pyrimidine biosynthesis, and
subsequent parasite death. Resistance to atovaquone in the field is associated with point …